MedWatch

Biomarin's dwarfism drug receives FDA approval

The growth hormone Voxzogo has been approved by the US Food and Drug Administration (FDA) as a treatment for achondroplasia in children.

Photo: Andrew Kelly/REUTERS / X02844

Biomarin's drug against achondroplasia, also known as dwarfism, has had a better start than most, and now the US-based biotech company can add another feather to its cap.

On Friday, the US Food and Drug administration (FDA) announced that it has granted the drug marketing approval, and thus the road has been cleared for Biomarin to reach the drug's biggest market in the world. The company is expecting to launch the Voxzogo in the US in mid-December.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs